DR REDDYS LABORATORIES LTD Q4 RESULTS
F&O outliers: September seasonality weighs on ICICI Bank, Adani Ports, TVS Motors, 7 others. Here's why
Over the last decade, five F&O stocks showed positive seasonality in September with average returns over 5%, including TVS Motor, Deepak Nitrite, Abbott India, Escorts Kubota, and Zee Entertainment. Conversely, ICICI Bank, APSEZ, SBI, Cummins India, and Dabur India had negative seasonality, with average losses of 2% or more.
Dr Reddy's Laboratories, TCS top stocks to buy post June quarter results: Siddhartha Khemka
The 1QFY25 corporate earnings report revealed both growth and challenges in India’s market. The Nifty50’s earnings rose 4% YoY, aided by companies like HDFC Bank and Tata Motors, despite setbacks from Oil Marketing Companies. The auto sector displayed strong volume growth, while IT services and healthcare sectors met expectations with promising future outlooks.
Nifty's 4% YoY Q1 PAT growth surpasses Motilal's estimates. Adani Ports and four others see FY25 earnings upgrades
Nifty achieved a 4% YoY growth in profit after tax (PAT), exceeding Motilal Oswal's 3% estimate, though it's the slowest growth since the pandemic quarter of 2020. Key contributors to this growth were HDFC Bank, Tata Motors, ICICI Bank, Maruti Suzuki, and Tata Consultancy Services (TCS), which together accounted for 127% of the incremental YoY earnings.
Ipca Labs Q1 Results: Net profit up 18% at Rs 192 crore
Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.
Apollo Hospitals Q1 Results: Profit zooms 83% YoY to Rs 305 crore, revenue up 15%
Apollo Hospitals Q1 Results: Leading hospital chain Apollo Hospitals reported 83% growth in its consolidated net profit at Rs 305 crore for the first quarter ended June 2024. It was Rs 167 crore in the year-ago period.
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
- Go To Page 1
Q1 results today: Godrej Consumer among 158 companies to announce earnings on Wednesday
Q1 results today: As the first quarter earnings season progressed, 158 companies, such as Pidilite, Godrej Consumer, NHPC, BSE, and ABFRL, announced their results. Godrej Consumer was projected to show a 46% increase in net profit but a slight dip in revenue. Kotak Securities highlighted growth in domestic volume and various categories.
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
D-St cheers Fed's dovish tone: Nifty surges past 25K milestone, Sensex sets new record
On Wednesday, the US Federal Reserve maintained its key interest rate at 5.25–5.5% for the eighth consecutive time, as expected, while signaling the possibility of a rate cut in its next meeting in September. From the Nifty stocks, Power Grid Corporation, Coal India, ONGC, HDFC Bank, and Dr Reddy's Laboratories were the top gainers, rising 2-4%. On the other hand, M&M, Tata Steel, Hero MotoCorp, Britannia, and Tata Motors ended with cuts.
Stocks in news: ICICI Bank, Adani Wilmar, ACC, Dr Reddy's, IndiGo, IndusInd Bank
Bandhan Bank on Friday reported 47% growth in its consolidated net profit at Rs 1,063 crore in the first quarter, compared with Rs 721 crore in the last year period.
Dr Reddy’s Laboratories board announces 1:5 stock split
Additionally the company has also announced that each American Depositary Share (ADS) will still represent 1 equity share. As a result, the number of ADSs held by each American Depositary Receipt holder will increase in proportion to the increase in equity shares.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Q1 results today: ICICI Bank, Dr Reddy's among 34 companies to announce earnings on Saturday
Finolex Industries, IEC Education, IFB Industries, J&K Bank, Jaiprakash Power, SBFC Finance, Vishal Fabrics, Spandana Sphoorty, Smruthi Organics, NTPC, Genus Power, Gujarat Cotex among others will also declare their June quarter results.
Dr Reddy's Q1 Preview: PAT may fall 4% YoY on pricing pressure, subdued US sales
In the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue from operations rose 12% year-on-year to Rs 7,083 crore.
Budget 2024, Q1 earnings action among 11 factors to impact D-Street mood this week
The short-term trend of Nifty seems to have reversed from all-time highs, Nagaraj Shetti of HDFC Securities said. The formation of candle patterns as per daily and weekly charts indicate the possibility of more weakness in the market ahead, he warned.
HDFC Bank, RIL among top 5 largecap additions by mutual funds in June
SBI MF, Kotak MF, Axis MF, Quant MF and Aditya Birla Sun Life MF were among the fund houses which shopped for HDFC Bank shares worth Rs 6,800 crore. At the end of June, the total number of shares held by all mutual funds in HDFC Bank stood at 154.26 crore versus 150.20 crore crore shares at the end of May.
Dr Reddy's, Sun Pharma recall drugs in US market: USFDA
Dr Reddy's Laboratories and Sun Pharma are recalling products in the US due to manufacturing issues, as per the latest USFDA Enforcement Report. Dr Reddy's is recalling insomnia and gout drugs, with 13,752 bottles of Eszopiclone tablets affected by failed impurities at their Bachupally plant. Sun Pharma is recalling 2,088 vials of Decitabine for Injection due to CGMP deviations at their Gujarat plant, prompting Class II recalls by both companies.
Apollo Hospitals Q4 Results: Net profit soars 77% YoY to Rs 258 crore; revenue jumps 15%
Apollo Hospitals Q4 Results: Revenue from operations for the January-March 2024 period increased 15% YoY to Rs 4,944 crore. The company's board has recommended a final dividend of Rs 10 per share for FY24. EBITDA for the fourth quarter stood at Rs 640 crore in the reporting March quarter, compared with Rs 488 crore in the same quarter a year earlier.
Divi’s Laboratories shares rally 5% post Q4 results. Should you buy, sell or hold?
Divi’s Laboratories saw a 5% surge in its shares on the BSE during Monday's trading session, reaching a new 52-week high of Rs 4,335. This rise came as brokerages such as Motilal Oswal and InCred expressed bullish sentiment towards the stock, following the company's impressive performance in Q4, where it reported a 68% year-on-year increase in profits, reaching Rs 538 crore.
Divi's Laboratories Q4 Results: Cons PAT soars 68% YoY to Rs 538 crore; dividend declared at Rs 30 per share
Divi's Laboratories Q4 Results: Net profit stood at Rs 321 crore in the corresponding quarter of the last financial year. The consolidated revenue in Q4 FY24 jumped 18% YoY to Rs 2,303 crore from Rs 1,951 crore reported in Q4 FY23. For the full financial year FY24, the consolidated profit after tax was reported at Rs 1,600 crore, a considerable drop from Rs 1,824 crore reported in FY23.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Results: Net profit jumps 36% YoY to Rs 1307 crore
Dr Reddy's has reported a 36% year-on-year jump in quarterly net profit, helped by increase in volumes of base business, new product launches, partially offset by price erosion in certain markets.
Q4 results today: PB Fintech, Dr Reddy's among 43 companies to announce results
Q4 results today: 43 companies are set to announce Q4 results, with Dr Reddy's and PB Fintech in focus. Dr Reddy's eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
Load More
